Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug molecule, TRIN 2755, to enter into Phase I clinical development
Subscribe to our email newsletter
Trin Pharma has appointed Stefan Wohlfeil as a new CEO of the company, effective from October 6, 2009.
Reportedly, Dr Stefan Wohlfeil previously held the position of chief medical officer at Trin Pharma. The change in management takes place at a time, where Trin Pharma is moving its lead molecule TRIN 2755 into Phase I clinical development.
Rudolf Reiter, former CEO of Ergonex, said: “I am pleased to pass the leadership of Trin Pharma on to Stefan Wohlfeil who has the right expertise to drive the clinical development of TRIN 2755. This will allow me to direct my full attention to Ergonex and the development of Terguride.”
Stefan Wohlfeil, CEO of Trin Pharma, said: “I am excited to take over from Rudolf Reiter at a time where our lead molecule is entering clinical development. I would like to thank Rudolf for his excellent work and many contributions during the build-up phase of TRIN Pharma.”